In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes

Miguel A. Pérez-Velasco , Julio Osuna-Sánchez , Mercedes Millán-Gómez , Michele Ricci , Almudena López-Sampalo , María-Rosa Bernal-López , Ricardo Gómez-Huelgas , Luis M. Pérez-Belmonte
{"title":"In-hospital linagliptin for management simplification and hypoglycemia reduction in very old patients with type 2 diabetes","authors":"Miguel A. Pérez-Velasco ,&nbsp;Julio Osuna-Sánchez ,&nbsp;Mercedes Millán-Gómez ,&nbsp;Michele Ricci ,&nbsp;Almudena López-Sampalo ,&nbsp;María-Rosa Bernal-López ,&nbsp;Ricardo Gómez-Huelgas ,&nbsp;Luis M. Pérez-Belmonte","doi":"10.1016/j.medcle.2024.10.023","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The role of in-hospital dipeptidyl peptidase-4 inhibitors in very old patients has not been widely described. This work analyzes the simplification of in-hospital antihyperglycemic management (less insulin use) and reductions in hypoglycemia events using linagliptin in patients aged<!--> <!-->≥<!--> <!-->80 years with type 2 diabetes.</div></div><div><h3>Patients and methods</h3><div>This real-world observational study included hospitalized patients<!--> <!-->≥<!--> <!-->80 years with type 2 diabetes treated with an antihyperglycemic protocol of either basal-bolus insulin or linagliptin between January 2016 and December 2023. A 1:1 propensity score matching analysis was performed.</div></div><div><h3>Results</h3><div>Post-matching, 944 patients were included in each group. The total and basal insulin doses and number of daily injections were significantly lower in the linagliptin group than the basal-bolus insulin group with no differences in glycemic efficacy. Regarding safety, patients on the basal-bolus insulin regimen had more hypoglycemic events. The use of basal-bolus insulin regimen (odds ratio: 4.22; 95% confidence interval: 2.14–6.28; <em>p</em> <!-->&lt;<!--> <!-->0.001), a higher total insulin dose (odds ratio: 3.55; 95% confidence interval: 2.02–5.36; <em>p</em> <!-->&lt;<!--> <!-->0.001) and the number of insulin injections (odds ratio: 2.86; 95% confidence interval: 1.50–4.12; <em>p</em> <!-->=<!--> <!-->0.002) were associated with a greater risk of hypoglycemia. Other hypoglycemia risk factors were older age, moderate–severe functional dependence, moderate–severe dementia, polypharmacy, and complex health status.</div></div><div><h3>Conclusions</h3><div>The linagliptin regimen simplified in-hospital antihyperglycemic management and reduced hypoglycemia events compared to basal-bolus insulin regimen in patients with type 2 diabetes aged<!--> <!-->≥<!--> <!-->80 years. Basal-bolus insulin use and clinical factors were associated with hypoglycemia. The linagliptin regimen could be considered as standard of care for older adult type 2 diabetes patients in the hospital setting.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 7","pages":"Pages 350-357"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020625001421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives

The role of in-hospital dipeptidyl peptidase-4 inhibitors in very old patients has not been widely described. This work analyzes the simplification of in-hospital antihyperglycemic management (less insulin use) and reductions in hypoglycemia events using linagliptin in patients aged  80 years with type 2 diabetes.

Patients and methods

This real-world observational study included hospitalized patients  80 years with type 2 diabetes treated with an antihyperglycemic protocol of either basal-bolus insulin or linagliptin between January 2016 and December 2023. A 1:1 propensity score matching analysis was performed.

Results

Post-matching, 944 patients were included in each group. The total and basal insulin doses and number of daily injections were significantly lower in the linagliptin group than the basal-bolus insulin group with no differences in glycemic efficacy. Regarding safety, patients on the basal-bolus insulin regimen had more hypoglycemic events. The use of basal-bolus insulin regimen (odds ratio: 4.22; 95% confidence interval: 2.14–6.28; p < 0.001), a higher total insulin dose (odds ratio: 3.55; 95% confidence interval: 2.02–5.36; p < 0.001) and the number of insulin injections (odds ratio: 2.86; 95% confidence interval: 1.50–4.12; p = 0.002) were associated with a greater risk of hypoglycemia. Other hypoglycemia risk factors were older age, moderate–severe functional dependence, moderate–severe dementia, polypharmacy, and complex health status.

Conclusions

The linagliptin regimen simplified in-hospital antihyperglycemic management and reduced hypoglycemia events compared to basal-bolus insulin regimen in patients with type 2 diabetes aged  80 years. Basal-bolus insulin use and clinical factors were associated with hypoglycemia. The linagliptin regimen could be considered as standard of care for older adult type 2 diabetes patients in the hospital setting.
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信